Drug Profile
Research programme: macrocyclic neuroprotective therapies - Neuren Pharmaceuticals
Alternative Names: NNZ 2599; NNZ 2606Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Neuren Pharmaceuticals
- Class Macrocyclic compounds
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurological disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Neurological-disorders(Prevention) in New Zealand
- 18 Apr 2006 This programme is still in active development
- 10 Jan 2005 Preclinical trials in Neurological disorders (Prevention) in New Zealand (unspecified route)